Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE: ABT) with an "overweight" rating and a price target of $131 ...

Shares of this maker of infant formula, medical devices and drugs have returned +4.9% over the past month versus the Zacks S&P 500 composite's +3.7% change. The Zacks Medical - Products industry, to ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.